GlassScriptPhysician profile
Angel A Lazo
NPI 1932168523
$195,124.11
in general payments reported to CMS, 2019-2025
50 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,313 · 2020: $1,804 · 2021: $2,597 · 2022: $82K · 2023: $33K · 2024: $35K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Food and Beverage: $10K · Honoraria: $5,500 · Travel and Lodging: $3,375 · Gift: $59.40 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,620.75 |
| Food and Beverage | $10,159.50 |
| Honoraria | $5,500.00 |
| Travel and Lodging | $3,375.35 |
| Gift | $59.40 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $94,390.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $50,312.20 | 2019-2025 | Xarelto, Spravato |
| Intuity Medical INC | $16,842.53 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Astrazeneca Pharmaceuticals LP | $14,462.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Intra-Sana Laboratories | $5,708.54 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Amgen INC. | $5,047.47 | 2019-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $1,049.28 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $908.31 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $814.64 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.09 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $485.16 | 2022-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbvie INC. | $425.98 | 2021-2025 | |
| Exact Sciences Corporation | $327.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $313.93 | 2021-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $242.74 | 2022-2024 | Endurant Iis |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Lazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.